“VistaGen Therapeutics Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates – A Tale of Ups and Downs”

Welcome to the world of VistaGen Therapeutics, Inc. A Bumpy Ride: Quarterly Loss Revealed It’s that time of year again – earnings season. Investors and analysts eagerly await the financial results of companies to determine their performance and potential future prospects. VistaGen Therapeutics, Inc. recently unveiled its quarterly loss of $0.46 per share, falling slightly…

Read More

Clever, Personable, and Unconventional: LS Cable System Receives $99 Million Investment Tax Credit Under Section 48C of the Inflation Reduction Act

LS Cable & System Welcomes $99 Million Investment Tax Credit Under Section 48C of the Inflation Reduction Act SEOUL, South Korea–(BUSINESS WIRE)– LS Cable & System Ltd. (“LS C&S”) welcomes the announcement that the United States Department of Energy (“DOE”) awarded LS GreenLink USA, Inc. (“LS GreenLink”) $99,060,000 in investment tax credits under Section 48C…

Read More

Revolutionizing Dermatological Treatment: Almirall and AbSci Join Forces in Groundbreaking AI Drug Discovery Partnership

Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, have announced a collaboration that will expand Absci’s…

Read More

Planview Takes the Lead Again: Named a Leader in Gartner’s Magic Quadrant for Strategic Portfolio Management for the Second Year in a Row!

Planview Positioned Furthest for Completeness of Vision AUSTIN, Texas–(BUSINESS WIRE)–Planview, the leading platform for connected work from portfolio planning to delivery, announced today that it was named a Leader in the April 2023 Gartner Magic Quadrant for Strategic Portfolio Management1 for the second year in a row, based on its Completeness of Vision and Ability…

Read More

Nanobiotix’s Upcoming Investor Conferences in February and March 2025

Nanobiotix’s Management to Participate in Fireside Chats at Upcoming Conferences Paris, France and Cambridge, MA, USA, January 29, 2025 – Nanobiotix, a leading late-clinical stage biotechnology company specializing in nanoparticle-based approaches to broaden treatment possibilities for patients dealing with cancer and other significant diseases, has announced that the Company’s management team will partake in fireside…

Read More

Crox Investor Alert: Bronstein, Gewirtz and Grossman, LLC Announces a Shareholder Class Action Lawsuit – Here’s What It Means for You

Class Action Lawsuit Filed Against Crocs, Inc.: What Does It Mean for Investors and the World? In a recent development, Bronstein, Gewirtz & Grossman, LLC, a renowned law firm, announced the filing of a class action lawsuit against Crocs, Inc. (Crocs or the Company) and certain of its officers. The lawsuit alleges securities law violations…

Read More